Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review Authors: Irma Melyani Puspitasari, Dimas Setyadi Putra, Alifa Nisa Deliyana, Nurqisthi Iqlima Adiputri, Lily Indriani Octovia, Sekar Ayu Paramita, Rano Kurnia Sinuraya Published: 2026 ABSTRACT AbstractObesity remains a major global public health challenge associated with increased morbidity, mortality, and reduced quality of life, necessitating effective treatment strategies beyond lifestyle modifications. The present scoping review aimed to synthesize recent evidence on the effectiveness and safety of anti-obesity medications (AOMs). A structured literature search was conducted in PubMed and Scopus in May 2025 to identify original studies published within the previous five years involving individuals with overweight or obesity receiving pharmacological interventions. A total of 42 articles representing 41 unique studies, predominantly randomized controlled trials (RCTs), were included in the evidence synthesis. The review encompassed glucagon-like peptide-1 receptor agonists (GLP-1 RA), including semaglutide, liraglutide, exenatide, and orforglipron; multi-receptor incretin agonists, including tirzepatide, retatrutide, and survodutide; amylin-based combination therapy (cagrilintide plus semaglutide); established non-incretin AOMs (orlistat, phentermine, phentermine/topiramate, and naltrexone/bupropion); microbiome-targeted therapies; and nutraceutical-based interventions. Among these, GLP-1 RA consistently demonstrated substantial weight-loss efficacy, with semaglutide achieving approximately 10–16% weight loss, while tirzepatide produced approximately 15–21% weight reduction over treatment durations of 20–70 weeks. Emerging multi-receptor incretin agonists also demonstrated promising efficacy, whereas established non-incretin AOMs, microbiome-targeted therapies, and nutraceutical-based interventions generally produced modest or more heterogeneous outcomes. Gastrointestinal adverse events (AEs) were the most frequently reported across incretin-based therapies. Overall, incretin-based therapies currently provide the greatest weight-loss benefit, although evidence for several emerging pharmacotherapies, microbiome-targeted therapies, and nutraceutical-based interventions remains limited. Further well-designed comparative trials, mechanistic studies, and long-term real-world investigations are needed to better establish the durability, safety, and clinical applicability of emerging AOMs. Introduction Obesity has become a major public health problem worldwide, characterized by excessive accumulation of body fat that poses a risk to health.1 The World Health Organization (WHO) defines overweight as a body mass index (BMI) of 25–29.9 kg/m2 and obesity as BMI ≥ 30 kg/m2 in the general population,2 whereas lower BMI thresholds (≥ 27.5 kg/m2) are recommended for Asian populations because obesity-related outcomes occur at lower BMI values.3 Although BMI remains the most widely used anthropometric measure for defining overweight and obesity, it does not fully capture body fat distribution.4 Therefore, additional anthropometric indices, such as waist circumference (WC) and waist-to-height ratio (WHtR), have been proposed to complement BMI in assessing central adiposity and obesity-related cardiometabolic risk, although their incremental value beyond BMI remains under investigation.4 Obesity is associated with an increased risk of comorbidities due to both pathophysiologic and mechanical effects of excess adiposity, including diabetes, cancer, and cardiovascular diseases.5 In 2022, the WHO estimated that approximately 2.5 billion adults (43%) worldwide were overweight, while 890 million (16%) were classified as obese.2 In response to the growing burden, various strategies have been developed to address the increasing prevalence of obesity, including lifestyle modification, pharmacological interventions, and surgical treatments.6,7 Lifestyle interventions (diet, behavior, and physical activity) remain the cornerstone of both prevention and treatment strategies.6 Pharmacological treatment has emerged as an important adjunct to lifestyle intervention. The United States Food and Drug Administration (FDA) has approved several anti-obesity medications (AOMs) for weight management. Short-term pharmacotherapy includes phentermine and diethylpropion, whereas long-term options include orlistat, phentermine-topiramate, bupropion-naltrexone, liraglutide 3.0mg, semaglutide 2.4 mg, tirzepatide, and setmelanotide.8 Setmelanotide is specifically approved for the treatment of obesity associated with pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency and is therefore not indicated for the management of general obesity.8 In addition, Gelesis100 (Plenity), a superabsorbent hydrogel composed of a cellulose–citric acid matrix that promotes satiety by increasing gastric fullness, has received FDA clearance as a medical device for weight management rather than approval as a pharmacological agent.8 Despite these advances, obesity remains a major global health challenge due to its strong association with metabolic disorders, cardiovascular diseases, and reduced quality of life (QoL), highlighting the urgency of finding effective treatment strategies beyond lifestyle modification alone.9 Recent reviews have summarized AOMs from specific perspectives, including mechanisms of action, FDA-approved and emerging pharmacological agents, oral AOMs, weight-loss maintenance, and pediatric obesity management.10–14 However, these reviews primarily focused on specific drug classes, therapeutic approaches, treatment settings, or patient populations, limiting the availability of a comprehensive overview of the current evidence. Therefore, the present scoping review aims to map the recent evidence on the effectiveness and safety of AOMs across different drug classes, study designs, and populations, while identifying emerging therapeutic approaches and evidence gaps to inform future research and clinical practice. Methods A scoping review was conducted using the Joanna Briggs Institute (JBI) framework for scoping reviews.15 The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) guideline was used to guide the conduct and reporting of the study.16 The PRISMA-ScR checklist is provided in Supplementary File 1. Eligibility Criteria Original research articles published in English within the previous five years (January 2020 to May 2025) were eligible for inclusion. Articles were included if they met all the following criteria: (1) involved human participants with overweight or obesity; (2) evaluated pharmacological interventions using AOMs; and (3) reported obesity-related treatment outcomes, including treatment effectiveness and/or safety. Studies were excluded if they were review articles, protocol papers, in vivo studies, inaccessible full-text publications, not related to obesity management, or did not evaluate the effectiveness of AOMs. Search Strategy A structured literature search was conducted in the PubMed and Scopus databases in May 2025 to identify recent studies evaluating the effectiveness and safety of AOMs. The search strategy was developed using the PCC (Population, Concept, and Context) framework, provided in Supplementary File 2 (Table S1). The population included individuals with overweight or obesity, the concept focused on AOMs, and the context comprised clinical studies evaluating treatment effectiveness and safety. The search strategy was predefined before study selection and was applied consistently throughout the review to ensure methodological transparency and reproducibility. The search strategy used the combination of the keywords “effectivity” OR “effectiveness” AND “anti-obesity drugs” OR “anti-obesity medicine”. Retrieved records were exported to Microsoft Excel for duplicate identification and removal. The complete search strategy is provided in Supplementary File 2 (Table S2). Study Selection The study selection was performed by two authors (AND and NIA). These authors independently assessed the potential eligibility of retrieved records through title and abstract screening, followed by full-text assessment of potentially eligible articles. The title, abstract, and full-text screening were further independently verified by a third reviewer (DSP). Any disagreements between the reviewers (AND and NIA) were resolved through discussion. If consensus could not be achieved, additional reviewers (IMP and RKS) were consulted to reach the final decision regarding study eligibility. Data Charting and Synthesis The data charting was independently conducted by two reviewers (AND and NIA) according to the predefined criteria. The following data from each included study were charted: author(s), publication year, country, study design, intervention, treatment duration, sample size, participant characteristics, statistical analysis, weight-loss outcomes, and reported adverse events (AEs). The data charting was further independently verified by a third reviewer (DSP). Any disagreements between the reviewers (AND and NIA) were resolved through discussion. If consensus could not be achieved, additional reviewers (IMP and RKS) were consulted to reach the final decision. A narrative synthesis of all included studies was conducted to evaluate the effectiveness and safety of AOMs. Results Search Results The structured literature search identified 291 records, comprising 188 records from PubMed and 103 records from Scopus. After the removal of nine duplicate records, 282 records remained for title and abstract screening. During the stage, 227 records were excluded because they were not related to obesity management (n = 140) or did not evaluate the effectiveness of AOMs (n = 87). Consequently, 55 reports were sought for full-text retrieval, of which six reports could not be retrieved. The remaining 49 full-text reports were assessed for eligibility, and seven reports were excluded, included protocol studies (n = 2), review articles (n = 4), and an in vivo study (n = 1). Ultimately, 42 publications representing 41 unique studies met the predefined inclusion criteria. Fox et al (2022)17 and Bensignor et al (2024)18 were identified as primary and secondary publications from the same randomized controlled trial (RCTs) and were considered as a single study during evidence synthesis to avoid double-counting. Figure 1 illustrates the study identification, screening, eligibility assessment, and inclusion process according to the PRISMA-ScR flow diagram. Figure 1PRISMA flow diagram for the literature search.The PRISMA flow diagram outlines the process of identifying studies via databases and registers. The identification phase shows 291 records identified through database searching, with 103 from Scopus and 188 from PubMed. Nine duplicate records were removed before screening, leaving 282 records. During screening, 227 records were excluded: 140 not related to obesity management and 87 not evaluating the effectiveness of AOMs. Fifty-five reports were sought for retrieval, with six not retrieved. Forty-nine reports were assessed for eligibility and seven were excluded: two protocol studies, four review articles and one in vivo study. Ultimately, 42 studies were included in the review.A PRISMA flow diagram for study identification, screening and inclusion process. PRISMA flow diagram for the literature search. Study Characteristics Table 1 summarizes the general characteristics of the studies. Most studies were conducted in North and South America (n = 15, 35.7%),17–31 followed by Asia Pacific (n = 10, 23.8%),42–51 multicenter/multinational studies (n = 10, 23.8%),32–41 and Europe (n = 7, 16.7%).52–58 Slightly more than half of the studies were published between 2023 and 2025 (n = 23, 54.8%),23,26,28,31,36–49,51,52,55,56 whereas the remaining studies were published between 2020 and 2022 (n = 19, 45.2%).17,19–22,24,25,27,29,30,32–35,50,53,54,57,58 RCTs were the predominant study design (n = 32, 76.2%),17,19,20,22,23,26,27,32–48,51–54,56–58 followed by cohort studies (n = 8, 19.0%),21,25,28–31,49,50 while one case report,24 and one survey,55 were also identified. Most studies enrolled adult participants (n = 36, 85.7%),19,21–33,35–39,41–50,52,54–58 whereas seven studies (16.7%) focused on adolescents.17,18,20,34,40,51,53Table 1General Characteristics of the Included StudiesStudy CharacteristicsStudies, n (%)ReferenceRegionNorth and South America15 (35.7)[17–31]Multicenter/multinational10 (23.8)[32–41]Asia Pacific10 (23.8)[42–51]Europe7 (16.7)[52–58]Publication year2023–202521 (50.0)[23,26,28,31,36–49,51,52,55,56]2020–202221 (50.0)[17–22,24,25,27,29,30,32–35,50,53,54,57,58]Study typeRandomized controlled trials (RCTs)32 (76.2)[17–20,22,23,26,27,32–48,51–54,56–58]Cohort8 (19.0)[21,25,28–31,49,50]Case report1 (2.4)[24]Survey1 (2.4)[55]Age group of study participantsAdults35 (83.3)[19,21–33,35–50,52,54–58]Adolescents7 (16.7)[17,18,20,34,40,51,53] Table 1General Characteristics of the Included StudiesStudy CharacteristicsStudies, n (%)ReferenceRegionNorth and South America15 (35.7)[17–31]Multicenter/multinational10 (23.8)[32–41]Asia Pacific10 (23.8)[42–51]Europe7 (16.7)[52–58]Publication year2023–202521 (50.0)[23,26,28,31,36–49,51,52,55,56]2020–202221 (50.0)[17–22,24,25,27,29,30,32–35,50,53,54,57,58]Study typeRandomized controlled trials (RCTs)32 (76.2)[17–20,22,23,26,27,32–48,51–54,56–58]Cohort8 (19.0)[21,25,28–31,49,50]Case report1 (2.4)[24]Survey1 (2.4)[55]Age group of study participantsAdults35 (83.3)[19,21–33,35–50,52,54–58]Adolescents7 (16.7)[17,18,20,34,40,51,53] General Characteristics of the Included Studies Category of AOMs Table 2 summarizes the categories of AOMs evaluated in the included studies. Among the Glucagon-like-peptide receptor agonists (GLP-1 RA), semaglutide was the most frequently investigated medication (n = 10, 23.8%),19,21,31–34,42,48,52,55 followed by exenatide, which was evaluated in four unique studies (n = 5, 11.9%) reported across five publications,17,18,20,23,53 whereas liraglutide,40 and orforglipron,39 were each evaluated in one study (2.4%). Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA, was investigated in five studies (11.9%),28,35,37,38,47 while combination cagrilintide and semaglutide,22 retatrutide,36 and survodutide,41 were each evaluated in one study (2.4%). Other pharmacological interventions included naltrexone/bupropion (n = 3, 7.1%),26,27,49 orlistat (n = 3, 7.1%),50,51,54 phentermine/topiramate (n = 2, 4.8%),24,43 phentermine (n = 1, 2.4%),25 and sibutramine (n = 1, 2.4%).57 In addition, three studies evaluated microbiome-based interventions,45,46,58 two investigated nutraceuticals,44,56 and two assessed multiple FDA-approved AOMs.29,30Table 2Category of AOMs Included StudiesCategoryAOMsStudies, n (%)ReferenceGLP-1 receptor agonistsSemaglutide10 (23.8)[19,21,31–34,42,48,52,55]Exenatide*5 (11.9)[17,18,20,23,53]Liraglutide1 (2.4)[40]Orforglipron1 (2.4)[39]Amylin analogue-GLP-1 receptor agonistCagrilintide-Semaglutide1 (2.4)[22]Dual GIP/GLP-1 receptor agonistTirzepatide5 (11.9)[28,35,37,38,47]Triple GIP/GLP-1/glucagon receptor agonistRetatrutide1 (2.4)[36]Dual GLP-1/glucagon receptor agonistSurvodutide1 (2.4)[41]Opioid antagonist/dopamine–norepinephrine reuptake inhibitorNaltrexone/Bupropion3 (7.1)[26,27,49]Lipase inhibitorOrlistat3 (7.1)[50,51,54]Sympathomimetic-anticonvulsant combinationPhentermine-Topiramate2 (4.8)[24,43]Sympathomimetic agentPhentermine1 (2.4)[25]Serotonin norepinephrine re-uptake inhibitorSibutramine1 (2.4)[57]Microbiome-based interventionsSynbiotic1 (2.4)[46]Bifidobacterium lactis IDCC 43011 (2.4)[45]Hafnia alvei HA4597®1 (2.4)[58]NutraceuticalsNeoagaro-oligosaccharides1 (2.4)[44]Bovine collagen1 (2.4)[56]Multiple FDA-approved AOMsMixed FDA-approved AOMs2 (4.8)[29,30]Note: *Fox et al (2022)17 and Bensignor et al (2024)18 represent primary and secondary analyses of the same RCTs.Abbreviations: AOMs, anti-obesity medications; GLP-1, glucagon-like peptide-1; GIP, glucose-dependent insulinotropic polypeptide. Table 2Category of AOMs Included StudiesCategoryAOMsStudies, n (%)ReferenceGLP-1 receptor agonistsSemaglutide10 (23.8)[19,21,31–34,42,48,52,55]Exenatide*5 (11.9)[17,18,20,23,53]Liraglutide1 (2.4)[40]Orforglipron1 (2.4)[39]Amylin analogue-GLP-1 receptor agonistCagrilintide-Semaglutide1 (2.4)[22]Dual GIP/GLP-1 receptor agonistTirzepatide5 (11.9)[28,35,37,38,47]Triple GIP/GLP-1/glucagon receptor agonistRetatrutide1 (2.4)[36]Dual GLP-1/glucagon receptor agonistSurvodutide1 (2.4)[41]Opioid antagonist/dopamine–norepinephrine reuptake inhibitorNaltrexone/Bupropion3 (7.1)[26,27,49]Lipase inhibitorOrlistat3 (7.1)[50,51,54]Sympathomimetic-anticonvulsant combinationPhentermine-Topiramate2 (4.8)[24,43]Sympathomimetic agentPhentermine1 (2.4)[25]Serotonin norepinephrine re-uptake inhibitorSibutramine1 (2.4)[57]Microbiome-based interventionsSynbiotic1 (2.4)[46]Bifidobacterium lactis IDCC 43011 (2.4)[45]Hafnia alvei HA4597®1 (2.4)[58]NutraceuticalsNeoagaro-oligosaccharides1 (2.4)[44]Bovine collagen1 (2.4)[56]Multiple FDA-approved AOMsMixed FDA-approved AOMs2 (4.8)[29,30]Note: *Fox et al (2022)17 and Bensignor et al (2024)18 represent primary and secondary analyses of the same RCTs.Abbreviations: AOMs, anti-obesity medications; GLP-1, glucagon-like peptide-1; GIP, glucose-dependent insulinotropic polypeptide. Category of AOMs Included Studies Note: *Fox et al (2022)17 and Bensignor et al (2024)18 represent primary and secondary analyses of the same RCTs. Abbreviations: AOMs, anti-obesity medications; GLP-1, glucagon-like peptide-1; GIP, glucose-dependent insulinotropic polypeptide. Result of Synthesis The detailed evidence synthesis of the included studies is presented in Supplementary File 2 (Table S3–S16). These tables summarize the characteristics of each study, including study design, intervention and comparator, treatment duration, populations, participant characteristics, statistical analyses, weight-loss outcomes, lifestyle interventions, safety outcomes, and conclusions. Discussion GLP-1 Receptor Agonist GLP-1 RA are analogs of incretin that facilitate insulin secretion in a glucose-dependent process and promote weight reduction by prolonging gastric emptying, inhibiting glucagon release, influencing the intestinal microbiome, and directly stimulating brain pathways to increase feelings of fullness.59 GLP-1 RA were the most extensively investigated class of AOMs, including semaglutide, exenatide, liraglutide, and orforglipron.17–21,23,31–34,39,40,42,48,52,53,55 Semaglutide Semaglutide is a long-acting human GLP-1 RA engineered to prolong receptor activation through enhanced albumin binding and resistance to dipeptidyl peptidase-4 (DPP-4) degradation, enabling once-weekly administration.60 These pharmacological properties may contribute to the sustained weight reduction consistently observed across RCTs and real-world studies.19,21,31–34,42,48,52,55 Oral semaglutide 50 mg achieved approximately 9.8% body-weight reduction after 20 weeks,52 whereas once-weekly subcutaneous semaglutide (1.7–2.4 mg) produced approximately 11.8–16.0% weight reduction over 44–68 weeks.19,32–34,42,48 Several studies also reported higher proportions of participants achieving clinically meaningful weight-loss thresholds (≥5% and ≥10%) than placebo,19,21,31,48 while observational studies confirmed that these benefits were largely maintained under routine clinical practice.21,31,55 Continued treatment appears essential for sustaining weight-loss benefits. A study reported that participants who discontinued semaglutide regained body weight during follow-up, whereas continued treatment-maintained weight reduction,32 reinforcing obesity as a chronic disease requiring long-term management. Gastrointestinal AEs, particularly nausea, vomiting, diarrhea, and constipation, were consistently the most frequently reported across studies.19,21,32–34,48,52 Gallbladder-related disorders, hepatobiliary events, and treatment discontinuation due to intolerance were reported less frequently, suggesting that semaglutide has an acceptable safety profile, although long-term tolerability should remain an important considerations during treatment.19,21,32–34 Exenatide Exenatide is a first-generation GLP-1 RA derived from exendin-4 that is naturally resistant to DPP-4 degradation, prolonging its biological activity despite its distinct molecular structure.61 Its pharmacological profile may contribute to the modest but clinically meaningful weight reduction observed across heterogenous clinical population.17,18,20,23,53 The greatest benefits were reported in adolescents with severe obesity, where once-weekly exenatide significantly reduced body weight, BMI, and waist circumference,53 and in adults receiving olanzapine, where exenatide attenuated antipsychotic-associated weight gain while improving insulin sensitivity and reducing hunger.23 These findings are clinically relevant given the well-established association between second-generation antipsychotics (SGAs), particularly olanzapine and clozapine, and substantial weight gain, metabolic dysfunction, increased cardiovascular risk, and reduce quality of life.62–65 The beneficial effects of exenatide are biologically plausible because GLP-1 RA suppress appetite and modulate central pathways, whereas olanzapine enhances food-related reward signaling, thereby promoting excessive energy intake.66–68 The effectiveness of exenatide appeared less consistent in hypothalamic obesity and during long-term weight-loss maintenance. Although significant reduction in BMI was observed in adolescents and young adults with hypothalamic obesity, improvement in body composition suggested potential metabolic benefits beyond absolute weight reuction.20 Likewise, the primary weight-loss maintenance trial in adolescents with severe obesity did not demonstrate significant differences in body weight or BMI after 52 weeks compared with placebo.17 However, a secondary analysis of the same cohort showed that lower postprandial leptin responses were associated with successful weight-loss maintenance among participants receiving exenatide,18 suggesting a potential role of exenatide in supporting weight-loss maintenance despite its modest effects on overall BMI reduction. Across the included studies, gastrointestinal AEs, including nausea, vomiting, diarrhea, abdominal pain, and constipation, were consistently the most frequently reported AEs.17,20,23,53 Serious AEs were uncommon and were generally unrelated to treatment, indicating that exenatide was overall well tolerated across the evaluated populations. Liraglutide Liraglutide is a human GLP-1 RA engineered with a fatty acid side chain that enhances albumin binding and resistance to DPP-4 degradation, prolonging its pharmacological activity and enabling once-daily administration.69 These pharmacological properties may contribute to the clinically meaningful weight reduction observed in adolescents with obesity.40 Liraglutide significantly improved the likelihood of achieving clinically meaningful BMI reduction compared with placebo, irrespective of baseline characteristics, while an early treatment response at week 16 predicted greater weight-loss success after 56 weeks.40 These findings suggest that early treatment response may help identify adolescents who are most likely to benefit from continued therapy, supporting a more individualized approach to obesity management. Although AEs data were not reported in the included study, the available evidence supports liraglutide as an effective treatment option for adolescents with obesity when combined with lifestyle intervention. Orforglipron Orforglipron is a first-in-class, orally active, non-peptide small-molecule GLP-1 RA that activates GLP-1 receptors without requiring an absorption enhancer or fasting restrictions,70 providing a convenient alternative to injectable GLP-1 RA. These pharmacological characteristics may contribute to the clinically meaningful weight reduction observed in adults with obesity.39 Once-daily oral orforglipron produced dose-dependent weight loss ranging from 9.4% to 14.7% after 36 weeks compared with 2.3% with placebo,39 while maintaining a safety profile generally comparable to injectable GLP-1 RA. Gastrointestinal AEs were the most frequently reported, whereas serious AEs were uncommon despite treatment discontinuation due to AEs occurring in 10–17% of participants.39 Collectively, these findings suggest that orforglipron represents a promising oral GLP-1 RA that combines substantial weight-loss efficacy with an acceptable safety profile, while potentially improving treatment acceptance among individuals reluctant to use injectable therapies. Multi-Receptor Incretin Agents Tirzepatide Tirzepatide is the first dual GIP and GLP-1 RA that simultaneously activates both incretin receptors, enhancing satiety and energy regulation through complementary metabolic pathway.71 These pharmacological properties may contribute to the substantial and sustained weight reduction consistently observed across RCTs and real-world studies.28,35,37,38,47 Weekly subcutaneous tirzepatide produced dose-dependent weight loss of approximately 15.0% to 21.3% after 52–72 weeks, significantly exceeding placebo across all RCTs.35,38,47 In addition to reducing body weight, tirzepatide improved body composition,38 while real-world evidence confirmed clinically meaningful weight reduction under routine clinical practice.28 Collectively, these findings demonstrated consistent weight-loss efficacy across both controlled and real-world settings. Continued treatment appears essential for maintaining these benefits. In the SURMOUNT-4 trial, participants who discontinued tirzepatide experienced substantial weight regain, whereas continued treatment maintained and further enhanced the initial weight reduction,37 reinforcing obesity as a chronic disease requiring long-term management. Gastrointestinal AEs, particularly nausea, diarrhoea, vomiting, and constipation, were the most frequently reported across studies,35,38,47 whereas serious AEs and treatment discontinuation due to AEs were uncommon,35,37,47 indicating an acceptable safety profile despite the substantial weight-loss efficacy observed. Retatrutide Retatrutide is the first triple agonist targeting the GLP-1, GIP, and glucagon receptors, combining appetite suppression with increased energy expenditure through complementary metabolic pathways.72 These complementary mechanisms may contribute to the substantial dose-dependent weight reduction observed in adults with obesity, with up to 83% of participants achieving ≥15% weight loss after 48 weeks of treatment.36 Retatrutide was generally well tolerated, with gastrointestinal AEs being the most common and serious AEs remaining uncommon despite treatment discontinuation in up to 16% of participants.36 Survodutide Survodutide is a dual glucagon receptor (GCGR) and GLP-1 RA that combines increased energy expenditure through glucagon receptor activation with appetite suppression mediated by GLP-1 RA.41 These complementary mechanisms may contribute to the clinically meaningful reductions in body weight observed across BMI subgroups in adults with overweight or obesity.41 Survodutide was generally well tolerated, with gastrointestinal AEs being the most frequently reported, although treatment discontinuation due to AEs occurred in up to 25% of participants.41 Cagrilintide-Semaglutide Cagrilintide-semaglutide combines an amylin analogue with a GLP-1 RA, simultaneously targeting complementary homeostatic and hedonic appetite pathways to enhance satiety and reduce energy intake beyond GLP-1 RA alone.73 These complementary mechanisms may contribute to the dose-dependent weight reduction observed in adults with overweight or obesity, with greater weight loss achieved across increasing cagrilintide doses when combined with semaglutide compared with semaglutide alone.22 The combination therapy was generally well tolerated, with gastrointestinal AEs being the most frequently reported and predominantly mild to moderate in severity, while no unexpected safety concerns were identified despite occasional serious AEs.22 Collectively, these findings suggest that dual amylin and GLP-1 receptor agonism represents a promising multi-target strategy for enhancing weight loss while maintaining an acceptable safety profile. Non-Incretin AOMs Naltrexone-Bupropion Naltrexone-bupropion exerts complementary effects on appetite regulation by enhancing hypothalamic satiety signalling and reducing food-related reward through activation of pro-opiomelanocortin (POMC) neurons by bupropion and blockade of autoinhibitory feedback by naltrexone, thereby prolonging appetite suppression.74 Clinical evidence suggests complementary mechanism translates into modest but clinically meaningful weight reduction, with additional improvements in body composition, including a more favourable lean-to-fat mass ratio when combined with lifestyle intervention.26 However, treatment response appeared to vary across patient populations, with less consistent weight-loss benefits observed in individuals with binge-eating disorder than in the general obesity population.27,49 Naltrexone-bupropion was generally well tolerated, although nausea, headache, dizziness, and insomnia were the most commonly reported AEs, and AEs appeared to occur more frequently among older individuals and those with obesity-related comorbidities.27,49 Phentermine and Phentermine-Topiramate Phentermine suppresses appetite primarily through enhanced hypothalamic norepinephrine signalling, whereas topiramate complements this effect through multiple neurochemical pathways that promote satiety and reduce energy intake.75,76 Clinical evidence suggests that phentermine provides clinically meaningful short-term weight reduction, with higher doses producing greater early improvements, although the benefit appeared to diminish over longer treatment durations.25 The addition of topiramate was associated with greater reductions in body weight and BMI when combined with lifestyle intervention, supporting the potential benefit of targeting multiple pathways involved in appetite regulation.24,43 Both treatments were generally well tolerated, with mostly mild AEs, including dry mouth, dizziness, headache, paraesthesia, constipation, and insomnia, whereas treatment discontinuation due to AEs was uncommon.24,25,43 Orlistat Orlistat promotes weight loss through a peripheral mechanism by inhibiting gastric and pancreatic lipases, thereby reducing intestinal fat absorption without directly affecting central appetite regulation.77 Clinical evidence suggests that orlistat provides modest weight reduction while offering additional metabolic benefits, including improvements in lipid profiles, insulin resistance, liver enzymes, and other non-alcoholic fatty liver disease-related parameters, particularly when combined with lifestyle intervention.50,51,54 However, its effect on body weight appeared less consistent in the absence of lifestyle modification.50 Orlistat was generally well tolerated, with gastrointestinal AEs, such as diarrhea, flatulence, and greasy stools, representing the most commonly reported treatment-related effects, while no unexpected safety concerns were identified.50,51,54 Sibutramine Sibutramine promotes weight loss by inhibiting the reuptake of serotonin and norepinephrine, thereby enhancing satiety and reducing energy intake.78 Although previously approved for both short- and long-term obesity treatment, sibutramine was withdrawn from the United States in 2010 because of an increased risk of cardiovascular events.78 In the present review, sibutramine combined with metformin achieved greater reductions in body weight and BMI than sibutramine combined with microcrystalline cellulose over 24 weeks, while both treatment regimens demonstrated favourable tolerability, with predominantly mild AEs and no severe AEs or treatment discontinuations reported.57 Notably, despite concerns regarding cardiovascular safety, sibutramine has not been associated with clinically significant hepatotoxicity, with only rare reports of clinically apparent acute liver injury.78 Microbiome Microbiome-based interventions encompass diverse approaches, including synbiotic formulations and strain-specific probiotic supplementation, each of which may influence weight regulation through different biological mechanisms. In the present review, the available evidence was heterogeneous, with synbiotic supplementation combined with dietary modification demonstrating greater improvements in body weight and fat mass, whereas individual probiotic strains showed more modest and variable effects on weight-related outcomes.45,46,58 Some studies additionally reported improvements in satiety and metabolic health parameters, suggesting that the potential benefits of these interventions may not be limited to body weight alone.45,58 Overall, all interventions demonstrated favourable safety profiles, although the limited number of studies and heterogeneity of formulations preclude firm conclusions regarding their comparative effectiveness. Nutraceuticals Nutraceutical-based interventions have attracted increasing interest as adjunctive strategies for obesity management because they comprise diverse naturally derived bioactive compounds with distinct mechanisms of action. In the present review, neoagaro-oligosaccharides derived from the seaweed Gelidium elegans and bovine collagen supplementation demonstrated favourable effects on weight-related outcomes, although the interventions differed substantially in their composition and proposed biological actions.44,56 In addition to reductions in body weight and BMI, bovine collagen supplementation was associated with improvements in waist circumference, fat mass, fatty liver index, and systolic blood pressure, suggesting potential metabolic benefits beyond weight reduction.56 Both interventions demonstrated favourable safety profiles, with no treatment-related safety concerns identified.44 However, given the limited number of studies and the heterogeneity of nutraceutical formulations, the current evidence remains insufficient to support broad clinical recommendations, and further well-designed RCTs are warranted. Multiple FDA-Approved AOMs Evidence from real-world clinical practice suggests that the effectiveness of FDA-approved AOMs extends beyond individual pharmacological efficacy and may be enhanced when integrated into comprehensive obesity management programmes. In a large retrospective cohort of veterans, pharmacotherapy was associated with clinically meaningful weight loss, with phentermine/topiramate demonstrating the greatest effectiveness among the evaluated medications, followed by liraglutide, lorcaserin, and orlistat.29 Likewise, participation in shared medical appointments with optional use of FDA-approved AOMs was associated with greater weight loss than usual care over up to two years of follow-up, highlighting the potential benefits of multidisciplinary and structured obesity care.30 AEs were not consistently reported across these real-world studies, although certain medications, such as lorcaserin, were subsequently withdrawn because of safety concerns.29 Overall, these findings suggest that integrating pharmacotherapy into coordinated obesity management programmes may improve long-term weight-loss outcomes in routine clinical practice. Strengths and Limitations The present scoping review has several strengths. First, the review provides a comprehensive overview of recent evidence on the effectiveness and safety of AOMs by synthesizing findings across multiple pharmacological classes, including GLP-1 RA, multi-receptor incretin agents, non-incretin AOMs, microbiome-based interventions, nutraceuticals, and evidence of multiple FDA-approved AOMs. The broad scope of the review enables comparison across diverse therapeutic approaches while highlighting emerging treatment strategies and current evidence gaps. Second, the review was conducted according to the JBI methodology and reported following the PRISMA-ScR guideline. Furthermore, study selection and data charting were independently performed by two reviewers and verified by a third reviewer, with disagreements resolved through discussion and additional reviewers when required, thereby enhancing the transparency and reproducibility of the review process. Nevertheless, several limitations should be acknowledged. The literature search was limited to PubMed and Scopus using a relatively narrow keyword strategy focused on AOMs and treatment effectiveness. Although this strategy was applied consistently throughout the review to preserve methodological transparency and reproducibility, it may have resulted in the omission of relevant studies, particularly those not captured by the predefined search terms. Furthermore, because the literature search was completed in May 2025, evidence published after the predefined search period was not incorporated into the present review. Consistent with the objectives and methodology of a scoping review, no formal risk-of-bias assessment or protocol registration were undertaken, and studies with different designs, including RCTs, cohort studies, a case report, and a survey, were synthesized narratively without weighting the certainty of evidence. Consequently, the findings should be interpreted as an evidence-mapping exercise rather than a quantitative comparison of treatment effects. Finally, because the evidence synthesis was qualitative, some degree of interpretation bias cannot be completely excluded. To minimise this risk, study selection, data charting, and evidence synthesis were conducted independently by multiple reviewers, with disagreements resolved through discussion and consensus, thereby supporting a balanced interpretation of the included evidence. Clinical Implication and Future Direction The available evidence synthesized in the present scoping review support the role of AOMs as an important adjunct to lifestyle intervention for the management of obesity. Among the evaluated pharmacotherapies, GLP-1 RA and multi-receptor incretin agents consistently demonstrated the greatest weight-loss efficacy. Semaglutide achieved approximately 10–16% weight reduction following 20–68 weeks of treatment, whereas tirzepatide demonstrated the largest and most sustained reductions, with approximately 15–21% weight loss after 52–72 weeks. Emerging therapies, including retatrutide and survodutide, also demonstrated promising weight-loss efficacy, although current evidence remains limited compared with semaglutide and tirzepatide. In contrast, established non-incretin AOMs, including phentermine, phentermine/topiramate, naltrexone-bupropion, and orlistat, generally produced more modest but clinically meaningful weight reduction and therefore remain appropriate therapeutic options for selected patients. Collectively, these findings suggest that treatment selection should be individualized according to patient characteristics, obesity-related comorbidities, treatment goals, potential AEs, accessibility, and long-term adherence rather than weight-loss efficacy alone. The observed weight regain following discontinuation of semaglutide and tirzepatide further reinforces obesity as a chronic disease requiring sustained long-term management rather than short-term pharmacotherapy alone. From a safety perspective, gastrointestinal AEs were consistently the most frequently reported across GLP-1 RA and multi-receptor incretin agents and were generally mild to moderate in severity. Clinicians should also consider the current regulatory status of individual medications when interpreting the available evidence. Although sibutramine demonstrated favourable short-term efficacy in the included study, it was withdrawn from the United States in 2010 because of an increased risk of cardiovascular events. Likewise, lorcaserin, which was evaluated in the real-world prescribing study included in the present review, has also been withdrawn because of safety concerns. Future research should prioritize adequately powered head-to-head comparative trials with standardized outcome measures and longer follow-up periods to better evaluate the comparative effectiveness, long-term durability, safety, adherence, and cost-effectiveness of currently available AOMs. Additional evidence is also needed to clarify the long-term clinical roles of emerging therapies, including multi-receptor incretin agents, microbiome-based interventions, and nutraceuticals, across more diverse patient populations before broader clinical implementation can be recommended. Conclusion The present scoping review demonstrates that AOMs differ substantially in their effectiveness and safety across pharmacological classes. Overall, incretin-based therapies, particularly GLP-1 receptor agonists and multi-receptor incretin agents, consistently demonstrated the greatest weight-loss efficacy, whereas established non-incretin anti-obesity medications remain clinically relevant for selected patients because of their established roles, availability, and patient-specific indications. These findings support an individualized treatment approach that considers not only weight-loss efficacy but also obesity-related comorbidities, safety profile, accessibility, and long-term adherence. Despite the encouraging efficacy of several emerging therapies, the current evidence remains limited for newer pharmacological agents, microbiome-based interventions, and nutraceuticals. Future research should prioritise well-designed head-to-head comparative trials with standardised outcome measures and longer follow-up to better evaluate long-term effectiveness, safety, durability, and real-world applicability across diverse patient populations.